Monograph
V08CA10 - Gadoxetic Acid |
Propably not porphyrinogenic |
PNP |
Rationale
Gadoxetic disodium is not metabolized by CYP enzymes.
Therapeutic characteristics
Gadoxetic acid is indicated for the detection of focal liver lesions and provides information on the character of lesions in T1-wighted magnetic resonance imaging (MRI). It is for diagnostic use by intravenous administration only.
Common side effects are nausea and headache.
Metabolism and pharmacokinetics
Gadoxetate disodium is not metabolized. It is excreted in the urine and feces. Elimination half-life is 1 hour.
It is highly water-soluble and less than 10% is bound to proteins in vivo.
Similar drugs
References
| # | Citation details | PMID |
|---|---|---|
| * | Summary of Product Characteristics | |
| 1. | Norwegian medicines agency. Summary of Product Characteristics (SPC). Primovist.
|
|
Tradenames
This list comprises raw data collected from different countries.
In some cases, a more comprehensive list of available drug packages is included.
Consequently, very similar terms may therefore appear multiple times.
Bold names are the searchable terms, while the gray names that follow are all mapped to the bolded term.
Note: The cleaning is done automatically by a proprietary algorithm, and it may produce errors.
We strive to improve it continuously.
Primovist 
Primovist · Primovist. 
Primovist 
Primovist 
Gadoxetate · Primovist 
Primovist 
Primovist 
Primovist 
Primovist 
Primovist 
Primovist
© NAPOS 2025